Baird raised the firm’s price target on Praxis Precision (PRAX) to $275 from $76 and keeps an Outperform rating on the shares.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PRAX:
- Midday Fly By: Salesforce targets $60B in revenue, TSMC reports Q3 beat
- Buy Rating Affirmed for Praxis Precision Medicines Following Positive Phase 3 Study Results
- Praxis Precision price target raised to $300 from $65 at Jefferies
- Praxis Precision price target raised to $350 from $155 at Guggenheim
- Why Is Praxis Precision Medicines (PRAX) Stock Up 155% Today?